A distinguished HEALTHPOINT BIOTHERAPEUTICS executive since 2008 and a member of the DFB Pharmaceuticals board of directors since 2004, Mr. Baugh brings nearly three decades of public and private company leadership experience to HEALTHPOINT BIOTHERAPEUTICS.

Most recently, Mr. Baugh was president and chief executive officer of LifeCap Resources, LLC, a consulting firm for venture capital groups and early-stage science companies. Prior to founding LifeCap in 2007, Mr. Baugh was CEO of MicroMed Cardiovascular, Inc., a medical device manufacturing company that developed the DeBakey VAD^®, a miniaturized ventricular assist device, in collaboration with NASA and Dr. Michael DeBakey’s team at the Baylor College of Medicine. In the company’s early stages, Mr. Baugh raised venture capital and bank financing and led the process of becoming a public company. In the early 1990s, Mr. Baugh served as both the senior vice president of finance and operations and the chief financial officer for Grasso Corporation, a publicly traded oil service company.

Mr. Baugh serves on the Foundation Board of the University of North Texas Health Science Center and the board of Tech Fort Worth, a nonprofit business incubator helping empower the local community and improve healthcare. He holds a bachelor of business administration in accounting from the University of Texas at Austin and is a Certified Public Accountant, currently licensed in New York and Texas.

Mr. Adams joined HEALTHPOINT in May 2010 with more than 18 years experience in senior sales, marketing, general management, and business development within the healthcare and bio-pharmaceutical industries. His experience includes an impressive career at Johnson & Johnson where he was recognized for consistently delivering exceptional sales volume, market share and profit growth across a variety of J&J businesses. While at J&J, Mr. Adams was Vice President Worldwide Sales and Patient Services for Animas Corporation, which provides insulin delivery products and glucose management systems. Brad accelerated sales growth by 38% making Animas J&J's fastest growing medical device company.

Prior to Animas, Brad was Vice President, Worldwide Sales for Therakos - one of J&J's bio-pharmaceutical companies, which markets Photopheresis drug/device therapy for Graft vs. Host Disease (GVHD) and Cutaneous T-Cell Lymphoma (CTLC). While there, Brad increased top line revenue 50% in two years. Brad also spent three years at J&J's Centocor business which markets an infused biologic, Remicade, for the treatment of Rheumatoid Arthritis, Chron's Disease, and Psoriasis. Brad was Region Business Director for the Mid-Atlantic and Northeast Regions where he was responsible for $300 million in annual sales in each region. In these roles, Brad drove both regions to #1 in sales ranking. Before leading the sales regions for Centocor, Brad was the Director of Private Payer Strategy/Managed Care Marketing.

Earlier in his career, Brad was the Managing Principal/General Manager for Johnson & Johnson Healthcare Systems - a Materials Management Solutions Consulting Practice, that provided strategic planning, operational assessment, and contracted materials management to hospitals and healthcare systems.

Prior to J&J, Brad worked in hospital administration, and was a commissioned officer in the US Army. Mr. Adams holds an undergraduate degree in Economics from Virginia Military Institute and a Master of Health Services Administration from The Medical College of Virginia.

Prior to his role as executive vice president, strategic and commercial development, Mr. Bancroft served as senior vice president, sales and marketing. Mr. Bancroft first joined HEALTHPOINT in 2004 as vice president of marketing. Before joining HEALTHPOINT, he was senior marketing director, global, for Botox^® Therapeutic at Allergan. While at Allergan, Mr. Bancroft contributed to the significant success of the Botox^® Therapeutic business by overhauling the business plan, defining the global competitive strategy, and leading a cross-functional team in developing the life-cycle management roadmap for the franchise. Mr. Bancroft began his career in sales of topical ophthalmics for Allergan’s U.S. eye care business in 1988.

Mr. Bancroft holds a bachelor of science degree in biology from Indiana University in Bloomington and a master’s degree in business administration in marketing and finance from the University of Southern California, Los Angeles.

 

Botox is a registered trademark of Allergan, Inc.

Robert Benkowski joined Healthpoint Biotherapeutics in 2011 as Vice President, Engineering. Mr. Benkowski has more than 18 years of experience in the medical industry, 10 of which were spent at MicroMed Cardiovascular, where he initially led the engineering efforts and ultimately led the operations. Prior to joining MicroMed, he was a contributor to the preliminary design work, and co-inventor on the technology that would later be known as the DeBakey VAD. He was with McDonnell Douglas Aerospace working at NASA-Johnson Space Center for the Space Station Project Office, and later at Baylor College of Medicine in Houston as Project Manager and Director of Surgical Engineering. He was co-PI on a joint grant with Texas Heart Institute, Rice University and University of Houston to develop a continuous flow artificial heart and most recently, he completed development, and received FDA approval for a butane powered blood warmer for the military MEDEVAC and civilian first responders.

Mr. Benkowski received his Executive MBA at the Bauer Business School, University of Houston, Texas in 2011, with honors, and his B.S. in Mechanical Engineering at the Ohio State University. He is the co-author of several patents and co-authored more than 50 papers and presentations. He has been an invited speaker and session chair of the joint FDA / NIH / NSF workshop on Computer Modeling and at the U.S.-Chinese-Russian Space Alliance Symposium at Rice. He also has the honor of being an inductee to the Space Technology Hall of Fame.

Mr. Christensen joined DFB Pharmaceuticals, Inc., in June 2007; he directs the human resources function for all of DFB’s affiliate companies. A multilingual, global HR executive, Mr. Christensen was most recently director of human resources for Celanese Corporation, a chemical products company headquartered in Dallas, Texas.

Mr. Christensen has more than 25 years of human resources experience and has held positions as director of human resources for Merck in Norway, Denmark, Sweden, and Finland; director of human resources for Merck Canada; head of human resources strategy and planning for Merck Corporation; and international human resources consultant for WFD Consulting.

Mr. Christensen is the co-author of several books and articles concerning the balance between work, life, and family; his work has been reviewed on Good Morning America, Fox News, and CNN. Mr. Christensen holds a bachelor’s degree in organizational psychology and a master’s degree in organizational behavior from Brigham Young University in Provo, Utah.

Bobbi Drais has more than 15 years of regulatory experience. Since joining HEALTHPOINT in 2003 and establishing the company’s regulatory department, Ms. Drais has achieved landmark regulatory success. She has been instrumental in securing new drug approval and marketing authorization approval for ATRALIN™ (tretinoin) Gel in the United States and Europe, respectively, and gaining regulatory approval of Collagenase SANTYL^® Ointment in Canada. Prior to joining the DFB family of companies, Ms. Drais was regulatory affairs manager for Galderma Laboratories, LP; Carrington Laboratories, Inc.; and Smith & Nephew, Inc.

Ms. Drais earned a bachelor of science degree in biology from Messiah College and a master of science degree in microbiology from the University of South Florida. Ms. Drais maintains memberships in the Regulatory Affairs Professional Society and the Drug Information Association, and she holds a Regulatory Affairs Certification (RAC).

Mr. Keith joined HEALTHPOINT in 2000. He has over 35 years experience in handling complex business transactions. While in private practice he represented diverse business entities such as national banks, private companies and public companies. Since joining Healthpoint, he has been involved in mergers and acquistions, licensing of technologies and commercial and financial transactions. He is a graduate of Western Illinois University and the Texas Tech University School of Law.

Mr. Lea has been with DFB Pharmaceuticals, Inc., since August 2002. He is responsible for DFB’s financing strategies, capital allocation decisions, and strategic planning, and leads HEALTHPOINT’s business development activities. Prior to joining DFB, Mr. Lea was an investment banker with Bank of America Securities. He was a member of an investment banking team that was responsible for the origination, structuring, and execution of capital raising, merger and acquisition, and general corporate finance advisory engagements with middle market companies in a variety of industries.

Mr. Lea holds the Chartered Financial Analyst (CFA) designation, and received a bachelor of arts degree in economics from Vanderbilt University in Nashville, Tennessee, and a master of business administration degree from The Fuqua School of Business at Duke University in Durham, North Carolina, where he graduated as a Fuqua Scholar.

Mr. Patterson has served as the chief financial officer of DFB Pharmaceuticals, Inc., the parent company of HEALTHPOINT, since 1996. He is a Texas-licensed CPA with experience in public accounting with PricewaterhouseCoopers. Having held financial and information technology positions with the Burnett Companies of Fort Worth, Texas, one of the founding entities of DFB Pharmaceuticals, Mr. Patterson participated in the acquisition of DPT Laboratories in 1990. He joined DPT Laboratories in 1991, heading up sales and marketing operations.

Mr. Patterson holds a bachelor’s degree and master’s degree in business from the University of Texas at Arlington.

Since joining the company in 1993, Mr. Santoro has been a key architect in the success of HEALTHPOINT. He was one of the first divisional sales managers hired to build the company’s original acute care field sales organization and was named Divisional Sales Manager of the Year two of his first four years. In 1998, Mr. Santoro was recruited to design and lead HEALTHPOINT’s Extended Care Division. Under his stewardship, this division became the company’s fastest-growing business in only two years. Additionally, Mr. Santoro played a significant role in the acquisition and development of two products that made HEALTHPOINT the leading provider of pharmaceuticals for the treatment of chronic wounds: PANAFIL^® Ointment and XENADERM^® Ointment.

Mr. Santoro began his career in wound care in 1989 and has since held various sales, training, and marketing positions. He earned a bachelor of science degree in business administration with a concentration in marketing from Indiana University.

Dr. Slade is a board-certified sub-specialist in clinical immunology with more than 15 years of industry-based experience in clinical research. After holding academic appointments at the University of Michigan and Cornell University Medical Center, he left academia to join the pharmaceutical industry. Dr. Slade worked with Jonas Salk, MD, on an HIV therapeutic vaccine project at Rhône-Poulenc Rorer and, in 1994, left his position as director of AIDS and immunology to join 3M Pharmaceuticals as director, worldwide medical and scientific affairs. Dr. Slade joined HEALTHPOINT in 2006.

Dr. Slade earned his undergraduate degree in biology from Hamilton College in Clinton, New York, followed by his medical degree from State University of New York (SUNY) Upstate Medical University in Syracuse, New York. He stayed at SUNY Upstate Medical Center to begin his residency in pediatrics, which he completed at C.S. Mott Children’s Hospital in Ann Arbor, Michigan. His residency was followed by a fellowship in clinical immunology at the University of Michigan, Ann Arbor.

Dr. Ronfard has more than 23 years of experience in the field of regenerative medicine. He started his career at the Blood Transfusion Center (Lille, France) where he developed a fibrin substrate to transplant human keratinocytes. He studied the fate of keratinocyte stem cells in Pr. Yann Barrandon’s lab in Paris for 5 years. He then moved to Biopredic International where he developed the use of human and animal hepatocytes for drug testing and screening. In 1997, he developed a new generation of tissue engineered products while senior scientist at Organogenesis Inc. In 2000, Dr. Ronfard served as director of research at Modex Therapeutics, an early pioneer in the field of tissue regeneration, where he was co-inventor of our 802 (Allox) cell therapy treatment for chronic wounds. In 2003, he joined L'Oreal (U.S.A. and Paris) where he served as associate Vice President/director of reconstructed skin worldwide. In this role he led the global research on skin engineering covering 40 researchers in the US, China and Europe. In 2006, Dr. Ronfard returned to Organogenesis as VP R&D to build a pipeline and a research team. Dr. Ronfard’s scientific expertise is uniquely focused in the areas that are of strategic importance to Healthpoint. He has numerous professional publications that have appeared in prestigious scientific journals. In addition, He is a recognized worldwide authority on cell therapy and has given more than 50 oral presentations or posters in international scientific meetings around the world. Dr. Ronfard earned a degree in Engineering in Agriculture from the University of Lille, France and has a PhD degree in Cell Biology from the University of Compiegne, France.